Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  2007-02-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00262-007-0283-6PMID 17273869PMCID PMC11030563
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ep-CAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic marker

  2006cited by this paper
• Phase I Trial of the Trifunctional Anti-HER2 × Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer

  2006cited by this paper
• Monoclonal and bispecific antibodies as novel therapeutics

  2006cited by this paper
• Retargeting T cells and immune effector cells with bispecific antibodies.

  2005cited by this paper
• Immunotherapy of malignant ascites with trifunctional antibodies

  2005cited by this paper
• New approaches to enhance chemotherapy in SCCHN.

  2005cited by this paper
• Lasting remission following multimodal treatment in a patient with metastatic breast cancer

  2005influential reference
• Trifunctional bispecific antibody–induced tumor cell lysis of squamous cell carcinomas of the upper aerodigestive tract

  2005influential reference
• [Long-term changes in peripheral blood leukocyte and lymphocyte populations in ENT-carcinoma patients. A flow cytometric study in 346 ENT-carcinoma patients and 31 healthy controls].

  2004cited by this paper
• Decreased Absolute Counts of T Lymphocyte Subsets and Their Relation to Disease in Squamous Cell Carcinoma of the Head and Neck

  2004cited by this paper
• Constitutive expression of CD69 in interspecies T-cell hybrids and locus assignment to human chromosome 12

  2004cited by this paper
• Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes.

  2004cited by this paper
• Recent advances in the generation of bispecific antibodies for tumor immunotherapy.

  2004cited by this paper
• Veränderungen von peripheren Blutzellpopulationen bei HNO-Karzinompatienten

  2004cited by this paper
• Recent advances in the generation of bispecific antibodies for tumor immunotherapy.

  2004cited by this paper
• Tumor-specific glycosylation of the carcinoma-associated epithelial cell adhesion molecule EpCAM in head and neck carcinomas.

  2003cited by this paper
• Bispecific antibody conjugates in therapeutics.

  2003cited by this paper
• Impaired monocyte function in cancer patients: restoration with a cyclooxygenase‐2 inhibitor

  2003cited by this paper
• Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends.

  2002cited by this paper
• Adoptive therapy with CD8 + T cells

  2002cited by this paper
• Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody.

  2001cited by this paper
• Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3).

  2001cited by this paper
• Lysis of Prostate Carcinoma Cells by Trifunctional Bispecific Antibodies (αEpCAM × αCD3)

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• The expression of Ep-CAM (17-1A) in squamous cell cancers of the lung.

  2000cited by this paper
• The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

  2000cited by this paper
• Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.

  1996cited by this paper
• Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies.

  1995cited by this paper
• Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily.

  1995cited by this paper
• Clinical screening of monoclonal antibodies 323/A3, cSF‐25 and K928 for suitability of targetting tumours in the upper aerodigestive and respiratory tract

  1994cited by this paper
• Pilot Study for the Evaluation of Simultaneous Cisplatin/5‐Fluorouracil Infusion and Limited Radiation Therapy in Regionally Recurrent Head and Neck Cancer (EST P‐C385)

  1994cited by this paper

• Monoclonal antibodies and antibody-drug conjugates as emerging therapeutics for breast cancer treatment.

  2023cites this paper
• Multispecific drugs herald a new era of biopharmaceutical innovation

  2020cites this paper
• T cell receptor modification by alpha and beta chain domain cross-over for adoptive T cell therapy

  2019cites this paper
• Entwicklung und Charakterisierung verschiedener neuartiger bispezifischer Antikörper basierend auf PankoMab-GEX™ zur Verbesserung der Tumortherapie

  2018influential citation
• Bispecific Antibodies: Formats and Areas of Application

  2018cites this paper
• Use of Nanoparticle Contrast Agents for Cell Tracking with Computed Tomography

  2017cites this paper
• A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3

  2015cites this paper
• Bispecific antibodies: an innovative arsenal to hunt, grab and destroy cancer cells.

  2015cites this paper
• Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer.

  2015cites this paper
• The Immune System in Head and Neck Squamous Cell Carcinoma: Interactions and Therapeutic Opportunities

  2014cites this paper
• Catumaxomab (Removab) – Trifunctional Antibodies: Combining Direct Tumor Cell Killing with Therapeutic Vaccination

  2014cites this paper
• The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities

  2013cites this paper
• Immunotherapy for head and neck cancer patients: shifting the balance.

  2013cites this paper
• Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dos

  2013cites this paper
• Immuntherapie von Kopf-Hals-Karzinomen

  2013cites this paper
• The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities

  2013cites this paper
• Cancer therapy with trifunctional antibodies: linking innate and adaptive immunity.

  2012cites this paper
• Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo

  2012cites this paper
• Trifunctional Triomab® Antibodies for Cancer Therapy

  2011influential citation
• [Pathogenesis and management of refractory malignant ascites].

  2011cites this paper
• Bispecific Antibodies for Arming Activated T Cells and Other Effector Cells for Tumor Therapy

  2011cites this paper
• Immunotherapy for head and neck cancer: advances and deficiencies

  2011cites this paper
• Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.

  2010cites this paper
• Emerging concepts for the treatment of hematological malignancies with therapeutic monoclonal antibodies.

  2010cites this paper
• Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action

  2010cites this paper
• Régime posologique pour l'administration d'un anticorps bispécifique epcamxcd3

  2010cites this paper
• Cancer therapy with bispecific antibodies: Clinical experience.

  2010cites this paper
• The tumor antigens RHAMM and G250/CAIX are expressed in head and neck squamous cell carcinomas and elicit specific CD8+ T cell responses.

  2009cites this paper
• Biological therapy of squamous cell cancers of the head and neck

  2009cites this paper
• Test System for Trifunctional Antibodies in 3D MCTS Culture

  2009cites this paper
• New cellular therapies: Is there a role for transfusion services?

  2009cites this paper
• Bispecific antibodies for cancer therapy.

  2009cites this paper
• Catumaxomab: a bispecific trifunctional antibody.

  2009cites this paper
• Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer.

  2008cites this paper
• Development and prospects for bispecific antibody-based therapeutics in cancer and other applications

  2008cites this paper
• Ertumaxomab: a trifunctional antibody for breast cancer treatment

  2008cites this paper
• Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody.

  2008cites this paper